<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161783</url>
  </required_header>
  <id_info>
    <org_study_id>2013OC003</org_study_id>
    <secondary_id>MT2013-06C</secondary_id>
    <nct_id>NCT02161783</nct_id>
  </id_info>
  <brief_title>Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a guideline for the treatment of graft failure after hematopoietic stem cell
      transplant (HSCT). This regimen, consisting of cyclophosphamide and fludarabine with low dose
      total body irradiation (TBI) is designed to promote donor engraftment by day 42 after initial
      graft failure.

      The graft will consist of bone marrow or G-CSF mobilized peripheral blood from a
      haploidentical related donor. The source of stem cells will be determined by the transplant
      team based on factors such as patient's age, medical history, donor availability and will be
      according to the current University of Minnesota Blood and Marrow Transplantation Program
      selection guidelines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of donor engraftment</measure>
    <time_frame>day 42</time_frame>
    <description>Rate of sustained donor engraftment at day 42 post this transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment related mortality</measure>
    <time_frame>day 100</time_frame>
    <description>Rate of treatment related mortality (TRM) at day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of survival</measure>
    <time_frame>Day 100</time_frame>
    <description>Rate of survival by day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of survival</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of survival at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease</measure>
    <time_frame>Day 100</time_frame>
    <description>Incidence of acute graft-versus-host disease by day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of chronic graft-versus-host disease at 1 year.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Primary Graft Failure</condition>
  <condition>Secondary Graft Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>TBI 200cGy in a single fraction on day -1 from transplant.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic stem cell infusion</intervention_name>
    <description>Hematopoietic stem cell infusion given on day 0.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Graft failure for
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary or secondary graft failure, as defined below, may receive a
             second transplant:

               -  Primary graft failure is defined as not achieving an ANC ≥0.5x10^9/L for three
                  consecutive days by day 35 - 42 following the first transplant.

               -  Secondary graft failure is defined as achieving an ANC ≥0.5x10^9/L for three
                  consecutive days by day 35 - 42, but subsequently drops below 0.5x10^9/L without
                  recovery.

               -  Loss of chimerism is defined as achieving an ANC ≥0.5x10^9/L for three
                  consecutive, but with less than 10% CD15+ donor cells in the marrow or peripheral
                  blood.

          -  Recipients should have acceptable organ function defined as:

               -  Renal: creatinine &lt; 2.0 (adults) and creatinine clearance &gt; 30. For creatinine
                  clearance &lt; 70, consultation with a BMT pharmacist is necessary for chemotherapy
                  dose adjustments.

               -  Hepatic: bilirubin, AST/ALT, ALP &lt; 10 x upper limit of normal

               -  Cardiac: left ventricular ejection fraction &gt; 40%

        Exclusion Criteria:

          -  Uncontrolled infection at the time of transplant.

          -  Patients with Fanconi Anemia or other DNA breakage syndromes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Troy C Lund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Krepski</last_name>
    <phone>612-273-2800</phone>
    <email>tkrepsk1@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Krepski</last_name>
      <phone>612-273-2800</phone>
      <email>tkrepsk1@fairview.org</email>
    </contact>
    <investigator>
      <last_name>Troy C Lund, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic stem cell transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

